Updates 22nd Century Group (NYSE: XXII) Citius Pharma (NASDAQ: CTXR) and Genprex (NASDAQ: GNPX)

Updates 22nd Century Group (NYSE: XXII) Citius Pharma (NASDAQ: CTXR) and Genprex (NASDAQ: GNPX)

Update 05/13/2021 (NASDAQ: RELI) our April 19th, 2021 report at $3.10/share announced an acquisition today and has broken above the 50DMA crossing $4.50 today for over 35% in bookable gains.

Reliance Global initial report

Good day everyone,

It appears that short sellers are fighting hard on GNPX this week. Over 20% in bookable gains with CTXR within 3 days. XXII had multiple swing opportunities however, like the other two we like the long term potential.

We are currently watching a few stocks that may be ready for a near-term breakout.

Our most recent report Genprex (NASDAQ: GNPX) had a great start breaking $4/share early on. The following two days of coverage GNPX traded between $3.40 to $3.90/share struggling with what appeared to be short attacks. Genprex gene therapy platform has a lot of potential. See our recent report here.

 

Citius Pharma (NASDAQ: CTXR) as many of you know we have consistently covered this company and their Mino-Lok product for a very long time. Short positions in this stock had increased to over 19% of the float as we reported on CTXR recently. From day one of our coverage the stock opened at $1.97/share and hit a high of $2.52 on day three for over 20% in bookable gains. See our latest report on CTXR here.

 

22nd Century Group (NYSE: XXII) we firmly believe in the proprietary tech, XXII holds over 200 patents on the tobacco and cannabis plants. This was not our first time reporting on XXII, but it has been a couple years. We think legislation may move this one closer to it’s true value many times higher than the current price. Full report on XXII available here.

Vote For Your Favorite Short Squeeze candidate On Our Active Twitter Poll

Together we’re strong,

The Traders News Group

Privacy Policy and Disclaimer

Tagged with